Natera, Inc. (NTRA) News
Filter NTRA News Items
NTRA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NTRA News Highlights
- For NTRA, its 30 day story count is now at 13.
- Over the past 22 days, NTRA's stories per day has been in a clear downtrend, falling by about 0.12 per 2 days.
- DNA and NOV are the most mentioned tickers in articles about NTRA.
Latest NTRA News From Around the Web
Below are the latest news stories about NATERA INC that investors may wish to consider to help them evaluate NTRA as an investment opportunity.
Natera to Participate in the Piper Sandler 34th Annual Healthcare ConferenceNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Steve Chapman, chief executive officer, and Mike Brophy, chief financial officer, will be presenting at the Piper Sandler 34th Annual Healthcare Conference located at the Lotte New York Palace on Wednesday, November 30 at 12:00 p.m. PT (3:00 p.m. ET). |
Biotech companies Natera and Synthego are laying off a total of 163 employeesA pair of biotechnology companies with offices on the Peninsula are cutting a combined 163 employees. Natera Inc. alerted state employment officials of its layoffs Nov. 4, the same day it notified 58 of its San Carlos-based workers that they were losing their jobs. Synthego Corp., meanwhile, alerted state authorities on Nov. 14 that it planned to cut 105 employees in Redwood City last Friday. |
New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma PatientsNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new study in Nature Medicine, which shows that its mPCR technology is able to assess response to tebentafusp in treatment-refractory metastatic uveal melanoma. The findings indicated an association between early reductions in ctDNA and longer overall survival, suggesting that traditional radiographic-based response criteria don't accurately reflect tebentafusp-related clinical activity and |
Natera Announces Pricing of Follow-On OfferingNatera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the pricing of its underwritten public offering of 11,430,000 shares of its common stock at a price to the public of $35.00 per share. Closing of the offering is expected to occur on November 18, 2022, subject to customary closing conditions. In addition, Natera has granted the underwriters a 30-day option to purchase up to an additional 1,714,500 shares of its common stock at the public offering price |
Natera Launches Proposed Follow-On OfferingNatera, Inc. (Nasdaq: NTRA) ("Natera"), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $350,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day option to purchase up to an additional $52,500,000 of shares of its common stock at the public offering price less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assura |
Natera Third Quarter 2022 Earnings: Beats ExpectationsNatera ( NASDAQ:NTRA ) Third Quarter 2022 Results Key Financial Results Revenue: US$210.6m (up 33% from 3Q 2021). Net... |
Natera (NTRA) Reports Q3 Loss, Tops Revenue EstimatesNatera (NTRA) delivered earnings and revenue surprises of 11.97% and 1.12%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Natera Reports Third Quarter 2022 Financial ResultsNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2022. |
Natera (NTRA) Shares Outperformed in the Third Quarter on Positive Business UpdatesAlger Capital, an investment management company, released its “Alger Spectra Fund” third quarter investor letter. A copy of the same can be downloaded here. In the third quarter, Class A shares of the fund outperformed the Russell 3000 Growth Index. In the quarter, the portfolio’s largest sector overweight was Health Care, and the largest sector underweight […] |
Natera gets MRD testing contract from US Dept of Veterans AffairsNatera (NTRA) said Wednesday it was awarded a nationwide contract by the U.S. Dept. of Veterans Affairs National Precision Oncology Program, effective Sept. 15.The contract is for minima… |